When it comes to treating chronic pain—or pain associated with surgery—clinicians are always looking for alternatives to opioids. “There are zero advantages to chronic opioid use,” says Earl Kilbride, MD, MHA, an orthopedic surgeon at the Austin Orthopedic Institute. While the US makes up about 4.4% of the global population, the country uses over 80% of the world’s opioids as well as an astonishing 99% of hydrocodone—a potent opioid with a high potential for abuse.
Alternatives are needed. Increasingly, ambulatory surgery centers (ASCs) like the one where Dr Kilbride works are exploring the benefits of peripheral nerve stimulation (PNS)—a minimally invasive outpatient procedure that involves connecting an electrode next to a nerve that is connected to wires and a small device outside the body. The market size for peripheral nerve stimulators is expected to reach over $253 million by 2033, up from some $105 million in 2024, with ASCs expected to see the fastest compound annual growth rate due to patients’ preference for outpatient care and healthcare models driven by efficiency.
While another neurostimulation therapy, called spinal cord stimulation, has been widely used and studied, peripheral nerve stimulation has only recently gained momentum. Its adoption has been stymied in part by reimbursement hurdles, lack of robust studies, and the need for more training and awareness.
Dr Kilbride is one of the physicians driving increased adoption of PNS at ASCs. At his practice, he says, some 10% to 20% of patients continue to experience ongoing pain after surgical procedures like total knee replacements. It is not always possible to determine the cause of this lingering pain, he notes, but it may be related to chronic nerve irritation or scar tissue—something outside the mechanical center of the knee that cannot be “fixed.” In addition, he has what he calls “gap patients” who are candidates for total knee replacements, but not yet able to have surgery for health reasons. In either case, he says, PNS offers an opioid-free way to bring relief.
A recent survey of pain physicians found that PNS was most often used to treat pain from major joint osteoarthritis and chronic lower back pain. Other common use cases included: neuropathic pain from peripheral neuralgia (94.7%), pericranial neuralgia (77.7%), and cancer-related neuropathic pain (64.9%). PNS-related clinical decision-making can vary significantly, the researchers found. Most doctors apply PNS before neuraxial neuromodulation when treating nonsurgical lower back pain (>50% for each form), but not before radiofrequency ablation (19.2%).
It is now believed that chronic inflammation of peripheral nerves drives patients’ chronic pain, and these nerves are sending ongoing abnormal signals. PNS acts directly on these nerves to ultimately reverse those neurologic changes, with lasting effects happening in as little as 60 days.
As a technology, PNS actually predated spinal cord stimulation. In 1967, two MIT researchers, Patrick Wall and William Sweet, demonstrated that by stimulating a patient’s peripheral nerve in the arm with an electrode, they could temporarily relieve chronic pain, meaning the perception of pain could be eliminated via a nonpainful electrical stimulus.
Following the finding, researchers developed a simple battery-powered device known as Transcutaneous Electrical Nerve Stimulation (TENS) that delivered alternating currents via electrodes attached near an area of pain. These pulses could be adjusted in frequency and intensity. While not as effective as addressing pain internally, versions of this device are still in use today, and pocket-sized versions can now be purchased from pharmacies for moderate pain relief.
But early implantable PNS devices were less successful—there were complications in implantations, the internal batteries were large and had to be replaced via surgery, and/or the wires often moved, making infections common.
That changed in the last decade with advances in wireless technology, surgical technique, and miniaturization. Today, using ultrasound, “we can visualize nerves and vasculature, and we can see where needles are being placed,” says Ramana Naidu, MD, medical director of pain management at MarinHealth Medical Center. In addition, large “paddles” delivering the electrical stimulation have been replaced by tiny wires. The company SPRINT, for instance, uses a MicroLead in their PNS device they claim to be “about the size of two human hairs.” And today’s wireless design involves an external power generator transmitting a signal to the lead to cause stimulation.
ASCs that handle a high volume of pain and orthopedic cases are likely to already have most of the equipment they need to perform PNS procedures on site. This includes an ultrasound machine to identify the target nerve, the peripheral nerve stimulator device (which ASCs performing nerve blocks would have), sterile equipment, and lead placement needles and stimulator leads.
Today’s PNS devices are so easy and adaptable, says Janet L. Carlson, MSN, BSN, RN, CRN, NE-BC, vice president of ASC operations at Commonwealth Pain and Spine in Kentucky, that it simply makes sense to integrate PNS procedures into existing protocols. “It’s been around but it’s not as popular as spinal cord stimulation,” she says. “It’s a newer technology that’s just now being recognized and adopted in patient treatment algorithms.”
Physicians performing PNS procedures are required to get specialized training through organizations like the World Academy of Pain Medicine United (WAPMU), the North American Neuromodulation Society (NANS), and device manufacturers like StimRouter and Nalu Medical that offer education and training. Nurses working at ASCs supporting these procedures can receive training via general perioperative courses such as those offered by AORN.
Carlson began working at ASCs after an early career as an ER nurse, after having been treated at an ASC as a patient. She gravitated toward work that allowed her to be actively involved in every stage of a patient’s journey, from pre-assessment and preoperative to PACU and Phase II. She has seen firsthand how PNS can both supplement other forms of treatment and reduce the need for opioids, thus improving patients’ quality of life.
For instance, she says, if an ASC is doing radiofrequency ablation—a procedure that involves destroying nerves with heat in order to prevent pain, which can cause muscle damage and often requires repeat procedures, “Why not consider adjunct therapy like PNS? It’s a small wire. You wear a receiver on the exterior of that wire and it works together to disrupt the pain,” she explains.
Carlson notes that in her practice, they most often use PNS for patients with chronic pain issues that have not been solved via physical therapy or injections. “We like to address the issue head on and reduce or eliminate opioids,” she says. “This way, we can help patients get back to daily living, feeling good and able to get around with none of the side effect issues.”
PNS is low-risk and patient-centered, and unlike other procedures, patients have the opportunity to trial the device for about a week. “They keep a diary and let us know how they are doing,” Carlson says. If the patient feels relief, he or she can then have it permanently inserted. There is also a 60-day percutaneous PNS treatment (using a needle to penetrate the skin) that provides sustained relief for various chronic pain issues, without requiring permanent implantation. Studies have shown percutaneous PNS to be an effective treatment for a number conditions, including chronic back pain, shoulder pain, knee pain, and post-amputation pain.
What is unique about PNS, says Dr Naidu, is “it should not alter the function or the structure of the nerve, so we can actually modulate the nerve without causing any mechanical or physical damage to it.” When “you turn off the electrical stimulation, that nerve is just functioning as it was, so you have that reversibility.”
Unlike with spinal cord stimulation, PNS has no battery, and the devices allow the patient to control the level of stimulation they need. “If my patient is going to the craft fair all weekend, she may turn it up for a few days and then go back to the level she was at before,” Dr Kilbride says. Typically patients cannot even feel the device working, he adds, but they feel the relief. He has seen these benefits compound over time. “We found that people use it less and less because the body is permanently ‘tricked,’ and it’s easily removed,” he says.
Of course, PNS is not without some risks. A 2023 study looking at adverse events from PNS medical device reports found that infection (22.7%), migration (14.7%), and skin erosion (9.4%) were the most commonly reported adverse events. Most of these were managed by removing the device.
There are a number of companies in the space, and PNS technology is rapidly evolving. The StimRouter, a long-term PNS device, includes a mobile app that allows patients full control in starting and stopping treatment, as well as in adjusting stimulation intensity.
“It’s really important we do a good job making the user interface easy for patients,” Dr Naidu says. “We want to make it easier for them to use it as far as recharging and how much the simulation is on.”
APRN guidelines released in July 2025 recommended the SPRINT 60-day PNS system, which includes a coiled lead to reduce wire migration and infection rates, for pain relief related to a number of conditions, including:
In looking at the use of the 60-day PNS system in patients post-amputation, one study found pain improved 58% in the PNS group at 8 weeks, compared to 14% in the placebo group. At 12 months, 67% of patients in the PNS group had over 50% pain relief, whereas none of the patients in the placebo group had similar relief.
In comparing PNS to other forms of pain relief, it is a win for patients—particularly those with chronic pain. Steroid injections provide only short-term relief; radiofrequency ablation has 60% to 80% success rates in reducing pain by over 50% but typically need to be repeated every 6 to 12 months. Spinal cord stimulation has comparable success rates to PNS, but is used for regional neuropathic pain such as failed back surgery syndrome or diabetic neuropathy.
The industry needs more studies related to PNS, says Carlson. And they are coming. “There’s more research available now, and more longitudinal studies coming,” she says. “That brings more credibility. I attended a large national pain conference recently, and there was a lot of coverage on PNS.”
A lack of high-quality, long-term randomized controlled trials has been a barrier to PNS adoption and broader insurance coverage. “Some 15 to 20 years ago, PNS was still not on the books for a lot of the payers,” says Dr Kilbride. “Now Medicare routinely covers it and federal-based insurance sometimes covers it. The way to get more access is to get results.”
ASCs are reimbursed for PNS procedures via CPT codes covering device implantation, revision, and removal, while Medicare and other payers approve it via a flat payment amount which varies by state, provided it meets requisite criteria such as: chronic and severe pain for at least three months, documented failure of less invasive treatments, and lack of surgical contraindications.
In 2020, the organization WAPMU released a statement arguing PNS was a medically necessary procedure for chronic pain patients that resulted in clinically significant reductions in opioid use, urging HCSC to cover the procedure. In 2023, the American Society of Anesthesiologists sent a similar letter to Blue Cross Blue Shield of Tennessee in response to draft language around PNS supporting its critical role as a treatment option for pain patients deserving of coverage.
And a number of companies with PNS devices have launched long-term studies to further demonstrate the benefits of PNS. For instance, Nalu Medical’s COMFORT study aims to demonstrate the effectiveness of their Neurostimulation System to treat chronic pain, following patients through 36 months. And in 2023, the company Curonix announced the results of an independent study showing that their Freedom PNS System improved pain scores by 70% and reduced medication use by 47% over a 24-month period.
A recent survey in the journal Neuromodulation captures the current state of PNS in practice, which has both high interest among clinicians and considerable variability in adoption. A total of 94 survey responses were collected from physicians who are members of NANS which includes both hospital and ASC physicians, most of whom were early and middle-career. Over 44% of respondents reported having performed over 10 PNS procedures in the past year.
One respondent, Corey Hunter, MD, assistant clinical professor at Mt Sinai Hospital, CEO of Ainsworth Ambulatory Surgery Center, and president of North American Neuromodulation Society, was quoted as saying: “I hope that commercial payers in the US will finally accept that PNS has a place in the treatment of chronic pain and should no longer be considered ‘experimental.’”
As access to peripheral nerve stimulation (PNS) continues to expand at ASCs, it is bringing not only increased opioid-free pain relief for patients suffering from chronic pain, but also significant cost savings for both providers and patients.
Cost benefits include:
Lower procedure costs. It is less expensive to perform a PNS procedure in an ASC than in a hospital outpatient department. ASCs have lower overhead costs and lower facility fees. Data from UnitedHealth Group found that ASCs can lower costs for hospital outpatient procedures by 59% under commercial insurance plans. Comparing the CPT code for percutaneous implantation of neurostimulator electrodes, peripheral nerve, the hospital outpatient Medicare facility fee is around $13,000 to $14,000, while the same fee is around $7,500 to $8,000 at an ASC (40% to 45% lower).
Avoiding long-term treatment costs. A single PNS procedure can help payers avoid years of ongoing healthcare costs needed for chronic pain management such as: prescriptions and prescription management; repeated corioceroid or nerve block injection; physical therapy; and specialist and ER visits.
Increased revenue stream. PNS is an effective, reimbursable procedure that can serve a number of chronic pain patients and act as a profitable new revenue stream for ASCs.
Increased efficiency. An average PNS procedure is completed in less than an hour, allowing ASCs to schedule multiple cases throughout the day and maximize their OR utilization, staff time, and profitability.
Significant savings for patients. A PNS procedure costs significantly less in an ASC than a hospital setting, and since it is a same-day outpatient procedure, it eliminates the cost of added hospital stays and travel time for multiple appointments.
—Brita Belli is an award-winning writer and PR professional with published stories in The New York Times, National Geographic, MSN.com, and Alternet.
Hope R. Am I a candidate for peripheral nerve stimulation (PNS)? Health Central. October 29, 2020.
Koff J. Pain doctors offer varied opinions on PNS applications. Neurotech Reports. November 2024.
Trent A R, Chopra P, Jain A. Peripheral Nerve Stimulator. STAT Pearls. March 13, 2023.
Wall P D, Sweet W H. Temporary Abolition of Pain in Man. Science. 1967;155(3758):108–109.